Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology

Overall, distinct profiles of TRAIL and its receptor expressions were evident in progression from normal endometrium to hyperplasia and cancer, which may indicate significance of TRAIL signaling in the course of endometrial carcinoma development.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Endometrial cancer is the sixth most common neoplasm in women worldwide, with a rising incidence largely attributed to the ongoing obesity epidemic.

📊

Key Findings & Data:Paraffin-embedded normal endometrium (n=18), endometrial hyperplasia (n=27), and endometrioid endometrial adenocarcinoma tissues (n=100) were analysed for TRAIL and receptor expression profiles via immunohistochemical staining.

💡

Conclusion & Impact:Overall, distinct profiles of TRAIL and its receptor expressions were evident in progression from normal endometrium to hyperplasia and cancer, which may indicate significance of TRAIL signaling in the course of endometrial carcinoma development.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

Endometrial cancer is the sixth most common neoplasm in women worldwide, with a rising incidence largely attributed to the ongoing obesity epidemic. TNF-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL receptors have been tested for their predictive, diagnostic, and prognostic values in various cancers, as well as for possible use in combination therapies. The roles of TRAIL and its receptors in endometrial tissue biology has not yet been cleared, and the potential of these molecules as biomarkers in endometrial cancer is yet to be defined. We investigated the expression profiles of TRAIL and its transmembrane receptors during endometrial carcinogenesis to evaluate their potential as prognostic markers. Paraffin-embedded normal endometrium (n=18), endometrial hyperplasia (n=27), and endometrioid endometrial adenocarcinoma tissues (n=100) were analysed for TRAIL and receptor expression profiles via immunohistochemical staining. Apoptotic indexes in the corresponding tissues were defined by TUNEL assay. Endometrial carcinoma displayed decreased TRAIL and DR4 expressions compared to the normal endometrium, while increased DR5 and decoy receptor (DcR1 and DcR2) expressions were evident. The complex atypical hyperplasia displayed the most similar expression profiles to the endometrial carcinoma, in accordance with the greatest risk of progression to endometrial carcinoma attributed to this tissue type. TRAIL/TRAIL receptor expression levels did not correlate with the prognostic factors of tumor stage or grade, or depth of myometrial invasion. Overall, distinct profiles of TRAIL and its receptor expressions were evident in progression from normal endometrium to hyperplasia and cancer, which may indicate significance of TRAIL signaling in the course of endometrial carcinoma development.

🔖

Cite This Article

ACAR, Ç. A., BİŞGİN, A., ŞANLIOĞLU, A. D., PEŞTERELİ, H. E., ERDOĞAN, G., ÖZBUDAK, İ. H., ŞİMŞEK, T., ŞANLIOĞLU, S. (2019). Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine, Cilt: 24 - Sayı: 3, 361–370. https://ajindex.com/articles/164468

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (17)

Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15: e268-278
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev 2017; 26: 444-457
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7- 30
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17
Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res 2005; 322: 53-61
Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13
Reed SD, Newton KM, Clinton WL et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200: 678.e1-6
Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662
Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6: 191-197
Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab 2013; 24: 578-587
Secchiero P, Gonelli A, Carnevale E et al. Evidence for a proangiogenic activity of TNFrelated apoptosis-inducing ligand. Neoplasia 2004; 6: 364-373
Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563
Wiley SR, Schooley K, Smolak PJ et al., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682
Pitti RM, Marsters SA, Ruppert S et al., Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690
Sanlioglu AD, Dirice E, Elpek O et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009; 38: 154-160
Sanlioglu AD, Dirice E, Elpek O et al. High levels of endogenous tumor necrosis factorrelated apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008; 36: 385-393
Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased s